General AML

SOHO 2019 | Is AML a disease susceptible to novel immunotherapies, such as CAR-T, DARTs, and BITEs?

L: English

During SOHO 2019, Houston, US, the AML Global Portal were pleased to interview Dr John DiPersio from Washington University Medical School, St. Louis, US, about the susceptibility of acute myeloid leukemia (AML) disease to novel immunotherapies, such as CAR-T cells, DARTs, and BITEs. He describes the challenges in overcoming the suppressive environment of AML and the lack of specific targets on malignant myeloid cells. He proceeds with the update on clinical advances in immune-based therapies and outlining future directions.